dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Santamarina Pérez, Estevo |
dc.contributor.author | Maisterra Santos, Olga |
dc.contributor.author | Sueiras Gil, Maria |
dc.contributor.author | Sarria Estrada, Silvana Isabel |
dc.contributor.author | Guzmán García, Lorena Carolina |
dc.contributor.author | Salas Puig, Xavier |
dc.contributor.author | Toledo Argany, Manuel |
dc.contributor.author | Abraira del Fresno, Laura |
dc.contributor.author | Alpuente Ruiz, Alicia |
dc.date.accessioned | 2019-04-09T11:22:06Z |
dc.date.available | 2019-04-09T11:22:06Z |
dc.date.issued | 2019-02-07 |
dc.identifier.citation | Santamarina E, Alpuente A, Maisterra O, Sueiras M, Sarria S, Guzman L, et al. Perampanel: A therapeutic alternative in refractory status epilepticus associated with MELAS syndrome. Epilepsy Behav Case Report. 2019;11:92–5. |
dc.identifier.issn | 2213-3232 |
dc.identifier.uri | https://hdl.handle.net/11351/4033 |
dc.description | MELAS; Perampanel; Status epilepticus |
dc.description.abstract | To our knowledge, there are no reports of status epilepticus (SE) associated with mitochondrial diseases and treated with perampanel (PER). We present three cases of patients with refractory SE associated with MELAS syndrome who responded favorably to PER. All cases were diagnosed as non-convulsive SE (focal without impairment of level of consciousness). After an initial treatment with other anti-seizure drugs, PER was added in all cases (8, 16 and 12 mg) and cessation of SE was observed within the next 4-8 hours. All the cases involved a stroke-like lesion present on brain MRI. In our patients, PER was an effective option in SE associated with MELAS syndrome. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Epilepsy and Behavior Case Reports;11 |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Epilèpsia - Tractament |
dc.subject | Encefalitis - Tractament |
dc.subject | Piridina |
dc.subject.mesh | Status Epilepticus |
dc.subject.mesh | MELAS Syndrome |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Pyridones |
dc.title | Perampanel: A therapeutic alternative in refractory status epilepticus associated with MELAS syndrome |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.ebcr.2019.01.008 |
dc.subject.decs | estado epiléptico |
dc.subject.decs | síndrome MELAS |
dc.subject.decs | /tratamiento farmacológico |
dc.subject.decs | piridonas |
dc.relation.publishversion | https://www.sciencedirect.com/science/article/pii/S2213323218301695?via%3Dihub#! |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Santamarina E, Alpuente A]Unitat d’Epilèpsia, Servei de Neurologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Maisterra O] Unitat Neurovascular, Servei de Neurologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Sueiras M] Unitat d’Electroencefalografia, Servei de Neurofisiologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Sarria S] Unitat MRI, Servei de Neuroradiologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Guzman L] Unitat d’Electroencefalografia, Servei de Neurofisiologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Abraira L, Salas-Puig J, Toledo M] Unitat d’Epilèpsia, Servei de Neurologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. |
dc.identifier.pmid | 30834194 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |